Full Text of HB5530 103rd General Assembly
HB5530enr 103RD GENERAL ASSEMBLY | | | HB5530 Enrolled | | LRB103 37122 RTM 67241 b |
|
| 1 | | AN ACT concerning regulation. | 2 | | Be it enacted by the People of the State of Illinois, | 3 | | represented in the General Assembly: | 4 | | Section 5. The Pharmacy Practice Act is amended by | 5 | | changing Section 3 as follows: | 6 | | (225 ILCS 85/3) | 7 | | (Section scheduled to be repealed on January 1, 2028) | 8 | | Sec. 3. Definitions. For the purpose of this Act, except | 9 | | where otherwise limited therein: | 10 | | (a) "Pharmacy" or "drugstore" means and includes every | 11 | | store, shop, pharmacy department, or other place where | 12 | | pharmacist care is provided by a pharmacist (1) where drugs, | 13 | | medicines, or poisons are dispensed, sold or offered for sale | 14 | | at retail, or displayed for sale at retail; or (2) where | 15 | | prescriptions of physicians, dentists, advanced practice | 16 | | registered nurses, physician assistants, veterinarians, | 17 | | podiatric physicians, or optometrists, within the limits of | 18 | | their licenses, are compounded, filled, or dispensed; or (3) | 19 | | which has upon it or displayed within it, or affixed to or used | 20 | | in connection with it, a sign bearing the word or words | 21 | | "Pharmacist", "Druggist", "Pharmacy", "Pharmaceutical Care", | 22 | | "Apothecary", "Drugstore", "Medicine Store", "Prescriptions", | 23 | | "Drugs", "Dispensary", "Medicines", or any word or words of |
| | | HB5530 Enrolled | - 2 - | LRB103 37122 RTM 67241 b |
|
| 1 | | similar or like import, either in the English language or any | 2 | | other language; or (4) where the characteristic prescription | 3 | | sign (Rx) or similar design is exhibited; or (5) any store, or | 4 | | shop, or other place with respect to which any of the above | 5 | | words, objects, signs or designs are used in any | 6 | | advertisement. | 7 | | (b) "Drugs" means and includes (1) articles recognized in | 8 | | the official United States Pharmacopoeia/National Formulary | 9 | | (USP/NF), or any supplement thereto and being intended for and | 10 | | having for their main use the diagnosis, cure, mitigation, | 11 | | treatment or prevention of disease in man or other animals, as | 12 | | approved by the United States Food and Drug Administration, | 13 | | but does not include devices or their components, parts, or | 14 | | accessories; and (2) all other articles intended for and | 15 | | having for their main use the diagnosis, cure, mitigation, | 16 | | treatment or prevention of disease in man or other animals, as | 17 | | approved by the United States Food and Drug Administration, | 18 | | but does not include devices or their components, parts, or | 19 | | accessories; and (3) articles (other than food) having for | 20 | | their main use and intended to affect the structure or any | 21 | | function of the body of man or other animals; and (4) articles | 22 | | having for their main use and intended for use as a component | 23 | | or any articles specified in clause (1), (2) or (3); but does | 24 | | not include devices or their components, parts or accessories. | 25 | | (c) "Medicines" means and includes all drugs intended for | 26 | | human or veterinary use approved by the United States Food and |
| | | HB5530 Enrolled | - 3 - | LRB103 37122 RTM 67241 b |
|
| 1 | | Drug Administration. | 2 | | (d) "Practice of pharmacy" means: | 3 | | (1) the interpretation and the provision of assistance | 4 | | in the monitoring, evaluation, and implementation of | 5 | | prescription drug orders; | 6 | | (2) the dispensing of prescription drug orders; | 7 | | (3) participation in drug and device selection; | 8 | | (4) drug administration limited to the administration | 9 | | of oral, topical, injectable, and inhalation as follows: | 10 | | (A) in the context of patient education on the | 11 | | proper use or delivery of medications; | 12 | | (B) vaccination of patients 7 years of age and | 13 | | older pursuant to a valid prescription or standing | 14 | | order, by a physician licensed to practice medicine in | 15 | | all its branches, except for vaccinations covered by | 16 | | paragraph (15), upon completion of appropriate | 17 | | training, including how to address contraindications | 18 | | and adverse reactions set forth by rule, with | 19 | | notification to the patient's physician and | 20 | | appropriate record retention, or pursuant to hospital | 21 | | pharmacy and therapeutics committee policies and | 22 | | procedures. Eligible vaccines are those listed on the | 23 | | U.S. Centers for Disease Control and Prevention (CDC) | 24 | | Recommended Immunization Schedule, the CDC's Health | 25 | | Information for International Travel, or the U.S. Food | 26 | | and Drug Administration's Vaccines Licensed and |
| | | HB5530 Enrolled | - 4 - | LRB103 37122 RTM 67241 b |
|
| 1 | | Authorized for Use in the United States. As applicable | 2 | | to the State's Medicaid program and other payers, | 3 | | vaccines ordered and administered in accordance with | 4 | | this subsection shall be covered and reimbursed at no | 5 | | less than the rate that the vaccine is reimbursed when | 6 | | ordered and administered by a physician; | 7 | | (B-5) (blank); following the initial | 8 | | administration of long-acting or extended-release form | 9 | | opioid antagonists by a physician licensed to practice | 10 | | medicine in all its branches, administration of | 11 | | injections of long-acting or extended-release form | 12 | | opioid antagonists for the treatment of substance use | 13 | | disorder, pursuant to a valid prescription by a | 14 | | physician licensed to practice medicine in all its | 15 | | branches, upon completion of appropriate training, | 16 | | including how to address contraindications and adverse | 17 | | reactions, including, but not limited to, respiratory | 18 | | depression and the performance of cardiopulmonary | 19 | | resuscitation, set forth by rule, with notification to | 20 | | the patient's physician and appropriate record | 21 | | retention, or pursuant to hospital pharmacy and | 22 | | therapeutics committee policies and procedures; | 23 | | (C) administration of injections of | 24 | | alpha-hydroxyprogesterone caproate, pursuant to a | 25 | | valid prescription, by a physician licensed to | 26 | | practice medicine in all its branches, upon completion |
| | | HB5530 Enrolled | - 5 - | LRB103 37122 RTM 67241 b |
|
| 1 | | of appropriate training, including how to address | 2 | | contraindications and adverse reactions set forth by | 3 | | rule, with notification to the patient's physician and | 4 | | appropriate record retention, or pursuant to hospital | 5 | | pharmacy and therapeutics committee policies and | 6 | | procedures; and | 7 | | (D) administration of long-acting injectables for | 8 | | mental health or substance use disorders injections of | 9 | | long-term antipsychotic medications pursuant to a | 10 | | valid prescription by the patient's a physician | 11 | | licensed to practice medicine in all its branches, | 12 | | advanced practice registered nurse, or physician | 13 | | assistant upon completion of appropriate training | 14 | | conducted by an Accreditation Council of | 15 | | Pharmaceutical Education accredited provider, | 16 | | including how to address contraindications and adverse | 17 | | reactions set forth by rule, with notification to the | 18 | | patient's physician and appropriate record retention, | 19 | | or pursuant to hospital pharmacy and therapeutics | 20 | | committee policies and procedures ; . | 21 | | (5) (blank); | 22 | | (6) drug regimen review; | 23 | | (7) drug or drug-related research; | 24 | | (8) the provision of patient counseling; | 25 | | (9) the practice of telepharmacy; | 26 | | (10) the provision of those acts or services necessary |
| | | HB5530 Enrolled | - 6 - | LRB103 37122 RTM 67241 b |
|
| 1 | | to provide pharmacist care; | 2 | | (11) medication therapy management; | 3 | | (12) the responsibility for compounding and labeling | 4 | | of drugs and devices (except labeling by a manufacturer, | 5 | | repackager, or distributor of non-prescription drugs and | 6 | | commercially packaged legend drugs and devices), proper | 7 | | and safe storage of drugs and devices, and maintenance of | 8 | | required records; | 9 | | (13) the assessment and consultation of patients and | 10 | | dispensing of hormonal contraceptives; | 11 | | (14) the initiation, dispensing, or administration of | 12 | | drugs, laboratory tests, assessments, referrals, and | 13 | | consultations for human immunodeficiency virus | 14 | | pre-exposure prophylaxis and human immunodeficiency virus | 15 | | post-exposure prophylaxis under Section 43.5; | 16 | | (15) vaccination of patients 7 years of age and older | 17 | | for COVID-19 or influenza subcutaneously, intramuscularly, | 18 | | or orally as authorized, approved, or licensed by the | 19 | | United States Food and Drug Administration, pursuant to | 20 | | the following conditions: | 21 | | (A) the vaccine must be authorized or licensed by | 22 | | the United States Food and Drug Administration; | 23 | | (B) the vaccine must be ordered and administered | 24 | | according to the Advisory Committee on Immunization | 25 | | Practices standard immunization schedule; | 26 | | (C) the pharmacist must complete a course of |
| | | HB5530 Enrolled | - 7 - | LRB103 37122 RTM 67241 b |
|
| 1 | | training accredited by the Accreditation Council on | 2 | | Pharmacy Education or a similar health authority or | 3 | | professional body approved by the Division of | 4 | | Professional Regulation; | 5 | | (D) the pharmacist must have a current certificate | 6 | | in basic cardiopulmonary resuscitation; | 7 | | (E) the pharmacist must complete, during each | 8 | | State licensing period, a minimum of 2 hours of | 9 | | immunization-related continuing pharmacy education | 10 | | approved by the Accreditation Council on Pharmacy | 11 | | Education; | 12 | | (F) the pharmacist must comply with recordkeeping | 13 | | and reporting requirements of the jurisdiction in | 14 | | which the pharmacist administers vaccines, including | 15 | | informing the patient's primary-care provider, when | 16 | | available, and complying with requirements whereby the | 17 | | person administering a vaccine must review the vaccine | 18 | | registry or other vaccination records prior to | 19 | | administering the vaccine; and | 20 | | (G) the pharmacist must inform the pharmacist's | 21 | | patients who are less than 18 years old, as well as the | 22 | | adult caregiver accompanying the child, of the | 23 | | importance of a well-child visit with a pediatrician | 24 | | or other licensed primary-care provider and must refer | 25 | | patients as appropriate; | 26 | | (16) the ordering and administration of COVID-19 |
| | | HB5530 Enrolled | - 8 - | LRB103 37122 RTM 67241 b |
|
| 1 | | therapeutics subcutaneously, intramuscularly, or orally | 2 | | with notification to the patient's physician and | 3 | | appropriate record retention or pursuant to hospital | 4 | | pharmacy and therapeutics committee policies and | 5 | | procedures. Eligible therapeutics are those approved, | 6 | | authorized, or licensed by the United States Food and Drug | 7 | | Administration and must be administered subcutaneously, | 8 | | intramuscularly, or orally in accordance with that | 9 | | approval, authorization, or licensing; and | 10 | | (17) the ordering and administration of tests and | 11 | | screenings for (i) influenza, (ii) SARS-COV 2, and (iii) | 12 | | health conditions identified by a statewide public health | 13 | | emergency, as defined in the Illinois Emergency Management | 14 | | Agency Act, with notification to the patient's physician | 15 | | and appropriate record retention or pursuant to hospital | 16 | | pharmacy and therapeutics committee policies and | 17 | | procedures. Eligible tests and screenings are those | 18 | | approved, authorized, or licensed by the United States | 19 | | Food and Drug Administration and must be administered in | 20 | | accordance with that approval, authorization, or | 21 | | licensing. | 22 | | A pharmacist who orders or administers tests or | 23 | | screenings for health conditions described in this | 24 | | paragraph may use a test that may guide clinical | 25 | | decision-making for the health condition that is waived | 26 | | under the federal Clinical Laboratory Improvement |
| | | HB5530 Enrolled | - 9 - | LRB103 37122 RTM 67241 b |
|
| 1 | | Amendments of 1988 and regulations promulgated thereunder | 2 | | or any established screening procedure that is established | 3 | | under a statewide protocol. | 4 | | A pharmacist may delegate the administrative and | 5 | | technical tasks of performing a test for the health | 6 | | conditions described in this paragraph to a registered | 7 | | pharmacy technician or student pharmacist acting under the | 8 | | supervision of the pharmacist. | 9 | | A pharmacist who performs any of the acts defined as the | 10 | | practice of pharmacy in this State must be actively licensed | 11 | | as a pharmacist under this Act. | 12 | | (e) "Prescription" means and includes any written, oral, | 13 | | facsimile, or electronically transmitted order for drugs or | 14 | | medical devices, issued by a physician licensed to practice | 15 | | medicine in all its branches, dentist, veterinarian, podiatric | 16 | | physician, or optometrist, within the limits of his or her | 17 | | license, by a physician assistant in accordance with | 18 | | subsection (f) of Section 4, or by an advanced practice | 19 | | registered nurse in accordance with subsection (g) of Section | 20 | | 4, containing the following: (1) name of the patient; (2) date | 21 | | when prescription was issued; (3) name and strength of drug or | 22 | | description of the medical device prescribed; and (4) | 23 | | quantity; (5) directions for use; (6) prescriber's name, | 24 | | address, and signature; and (7) DEA registration number where | 25 | | required, for controlled substances. The prescription may, but | 26 | | is not required to, list the illness, disease, or condition |
| | | HB5530 Enrolled | - 10 - | LRB103 37122 RTM 67241 b |
|
| 1 | | for which the drug or device is being prescribed. DEA | 2 | | registration numbers shall not be required on inpatient drug | 3 | | orders. A prescription for medication other than controlled | 4 | | substances shall be valid for up to 15 months from the date | 5 | | issued for the purpose of refills, unless the prescription | 6 | | states otherwise. | 7 | | (f) "Person" means and includes a natural person, | 8 | | partnership, association, corporation, government entity, or | 9 | | any other legal entity. | 10 | | (g) "Department" means the Department of Financial and | 11 | | Professional Regulation. | 12 | | (h) "Board of Pharmacy" or "Board" means the State Board | 13 | | of Pharmacy of the Department of Financial and Professional | 14 | | Regulation. | 15 | | (i) "Secretary" means the Secretary of Financial and | 16 | | Professional Regulation. | 17 | | (j) "Drug product selection" means the interchange for a | 18 | | prescribed pharmaceutical product in accordance with Section | 19 | | 25 of this Act and Section 3.14 of the Illinois Food, Drug and | 20 | | Cosmetic Act. | 21 | | (k) "Inpatient drug order" means an order issued by an | 22 | | authorized prescriber for a resident or patient of a facility | 23 | | licensed under the Nursing Home Care Act, the ID/DD Community | 24 | | Care Act, the MC/DD Act, the Specialized Mental Health | 25 | | Rehabilitation Act of 2013, the Hospital Licensing Act, or the | 26 | | University of Illinois Hospital Act, or a facility which is |
| | | HB5530 Enrolled | - 11 - | LRB103 37122 RTM 67241 b |
|
| 1 | | operated by the Department of Human Services (as successor to | 2 | | the Department of Mental Health and Developmental | 3 | | Disabilities) or the Department of Corrections. | 4 | | (k-5) "Pharmacist" means an individual health care | 5 | | professional and provider currently licensed by this State to | 6 | | engage in the practice of pharmacy. | 7 | | (l) "Pharmacist in charge" means the licensed pharmacist | 8 | | whose name appears on a pharmacy license and who is | 9 | | responsible for all aspects of the operation related to the | 10 | | practice of pharmacy. | 11 | | (m) "Dispense" or "dispensing" means the interpretation, | 12 | | evaluation, and implementation of a prescription drug order, | 13 | | including the preparation and delivery of a drug or device to a | 14 | | patient or patient's agent in a suitable container | 15 | | appropriately labeled for subsequent administration to or use | 16 | | by a patient in accordance with applicable State and federal | 17 | | laws and regulations. "Dispense" or "dispensing" does not mean | 18 | | the physical delivery to a patient or a patient's | 19 | | representative in a home or institution by a designee of a | 20 | | pharmacist or by common carrier. "Dispense" or "dispensing" | 21 | | also does not mean the physical delivery of a drug or medical | 22 | | device to a patient or patient's representative by a | 23 | | pharmacist's designee within a pharmacy or drugstore while the | 24 | | pharmacist is on duty and the pharmacy is open. | 25 | | (n) "Nonresident pharmacy" means a pharmacy that is | 26 | | located in a state, commonwealth, or territory of the United |
| | | HB5530 Enrolled | - 12 - | LRB103 37122 RTM 67241 b |
|
| 1 | | States, other than Illinois, that delivers, dispenses, or | 2 | | distributes, through the United States Postal Service, | 3 | | commercially acceptable parcel delivery service, or other | 4 | | common carrier, to Illinois residents, any substance which | 5 | | requires a prescription. | 6 | | (o) "Compounding" means the preparation and mixing of | 7 | | components, excluding flavorings, (1) as the result of a | 8 | | prescriber's prescription drug order or initiative based on | 9 | | the prescriber-patient-pharmacist relationship in the course | 10 | | of professional practice or (2) for the purpose of, or | 11 | | incident to, research, teaching, or chemical analysis and not | 12 | | for sale or dispensing. "Compounding" includes the preparation | 13 | | of drugs or devices in anticipation of receiving prescription | 14 | | drug orders based on routine, regularly observed dispensing | 15 | | patterns. Commercially available products may be compounded | 16 | | for dispensing to individual patients only if all of the | 17 | | following conditions are met: (i) the commercial product is | 18 | | not reasonably available from normal distribution channels in | 19 | | a timely manner to meet the patient's needs and (ii) the | 20 | | prescribing practitioner has requested that the drug be | 21 | | compounded. | 22 | | (p) (Blank). | 23 | | (q) (Blank). | 24 | | (r) "Patient counseling" means the communication between a | 25 | | pharmacist or a student pharmacist under the supervision of a | 26 | | pharmacist and a patient or the patient's representative about |
| | | HB5530 Enrolled | - 13 - | LRB103 37122 RTM 67241 b |
|
| 1 | | the patient's medication or device for the purpose of | 2 | | optimizing proper use of prescription medications or devices. | 3 | | "Patient counseling" may include without limitation (1) | 4 | | obtaining a medication history; (2) acquiring a patient's | 5 | | allergies and health conditions; (3) facilitation of the | 6 | | patient's understanding of the intended use of the medication; | 7 | | (4) proper directions for use; (5) significant potential | 8 | | adverse events; (6) potential food-drug interactions; and (7) | 9 | | the need to be compliant with the medication therapy. A | 10 | | pharmacy technician may only participate in the following | 11 | | aspects of patient counseling under the supervision of a | 12 | | pharmacist: (1) obtaining medication history; (2) providing | 13 | | the offer for counseling by a pharmacist or student | 14 | | pharmacist; and (3) acquiring a patient's allergies and health | 15 | | conditions. | 16 | | (s) "Patient profiles" or "patient drug therapy record" | 17 | | means the obtaining, recording, and maintenance of patient | 18 | | prescription information, including prescriptions for | 19 | | controlled substances, and personal information. | 20 | | (t) (Blank). | 21 | | (u) "Medical device" or "device" means an instrument, | 22 | | apparatus, implement, machine, contrivance, implant, in vitro | 23 | | reagent, or other similar or related article, including any | 24 | | component part or accessory, required under federal law to | 25 | | bear the label "Caution: Federal law requires dispensing by or | 26 | | on the order of a physician". A seller of goods and services |
| | | HB5530 Enrolled | - 14 - | LRB103 37122 RTM 67241 b |
|
| 1 | | who, only for the purpose of retail sales, compounds, sells, | 2 | | rents, or leases medical devices shall not, by reasons | 3 | | thereof, be required to be a licensed pharmacy. | 4 | | (v) "Unique identifier" means an electronic signature, | 5 | | handwritten signature or initials, thumb print, or other | 6 | | acceptable biometric or electronic identification process as | 7 | | approved by the Department. | 8 | | (w) "Current usual and customary retail price" means the | 9 | | price that a pharmacy charges to a non-third-party payor. | 10 | | (x) "Automated pharmacy system" means a mechanical system | 11 | | located within the confines of the pharmacy or remote location | 12 | | that performs operations or activities, other than compounding | 13 | | or administration, relative to storage, packaging, dispensing, | 14 | | or distribution of medication, and which collects, controls, | 15 | | and maintains all transaction information. | 16 | | (y) "Drug regimen review" means and includes the | 17 | | evaluation of prescription drug orders and patient records for | 18 | | (1) known allergies; (2) drug or potential therapy | 19 | | contraindications; (3) reasonable dose, duration of use, and | 20 | | route of administration, taking into consideration factors | 21 | | such as age, gender, and contraindications; (4) reasonable | 22 | | directions for use; (5) potential or actual adverse drug | 23 | | reactions; (6) drug-drug interactions; (7) drug-food | 24 | | interactions; (8) drug-disease contraindications; (9) | 25 | | therapeutic duplication; (10) patient laboratory values when | 26 | | authorized and available; (11) proper utilization (including |
| | | HB5530 Enrolled | - 15 - | LRB103 37122 RTM 67241 b |
|
| 1 | | over or under utilization) and optimum therapeutic outcomes; | 2 | | and (12) abuse and misuse. | 3 | | (z) "Electronically transmitted prescription" means a | 4 | | prescription that is created, recorded, or stored by | 5 | | electronic means; issued and validated with an electronic | 6 | | signature; and transmitted by electronic means directly from | 7 | | the prescriber to a pharmacy. An electronic prescription is | 8 | | not an image of a physical prescription that is transferred by | 9 | | electronic means from computer to computer, facsimile to | 10 | | facsimile, or facsimile to computer. | 11 | | (aa) "Medication therapy management services" means a | 12 | | distinct service or group of services offered by licensed | 13 | | pharmacists, physicians licensed to practice medicine in all | 14 | | its branches, advanced practice registered nurses authorized | 15 | | in a written agreement with a physician licensed to practice | 16 | | medicine in all its branches, or physician assistants | 17 | | authorized in guidelines by a supervising physician that | 18 | | optimize therapeutic outcomes for individual patients through | 19 | | improved medication use. In a retail or other non-hospital | 20 | | pharmacy, medication therapy management services shall consist | 21 | | of the evaluation of prescription drug orders and patient | 22 | | medication records to resolve conflicts with the following: | 23 | | (1) known allergies; | 24 | | (2) drug or potential therapy contraindications; | 25 | | (3) reasonable dose, duration of use, and route of | 26 | | administration, taking into consideration factors such as |
| | | HB5530 Enrolled | - 16 - | LRB103 37122 RTM 67241 b |
|
| 1 | | age, gender, and contraindications; | 2 | | (4) reasonable directions for use; | 3 | | (5) potential or actual adverse drug reactions; | 4 | | (6) drug-drug interactions; | 5 | | (7) drug-food interactions; | 6 | | (8) drug-disease contraindications; | 7 | | (9) identification of therapeutic duplication; | 8 | | (10) patient laboratory values when authorized and | 9 | | available; | 10 | | (11) proper utilization (including over or under | 11 | | utilization) and optimum therapeutic outcomes; and | 12 | | (12) drug abuse and misuse. | 13 | | "Medication therapy management services" includes the | 14 | | following: | 15 | | (1) documenting the services delivered and | 16 | | communicating the information provided to patients' | 17 | | prescribers within an appropriate time frame, not to | 18 | | exceed 48 hours; | 19 | | (2) providing patient counseling designed to enhance a | 20 | | patient's understanding and the appropriate use of his or | 21 | | her medications; and | 22 | | (3) providing information, support services, and | 23 | | resources designed to enhance a patient's adherence with | 24 | | his or her prescribed therapeutic regimens. | 25 | | "Medication therapy management services" may also include | 26 | | patient care functions authorized by a physician licensed to |
| | | HB5530 Enrolled | - 17 - | LRB103 37122 RTM 67241 b |
|
| 1 | | practice medicine in all its branches for his or her | 2 | | identified patient or groups of patients under specified | 3 | | conditions or limitations in a standing order from the | 4 | | physician. | 5 | | "Medication therapy management services" in a licensed | 6 | | hospital may also include the following: | 7 | | (1) reviewing assessments of the patient's health | 8 | | status; and | 9 | | (2) following protocols of a hospital pharmacy and | 10 | | therapeutics committee with respect to the fulfillment of | 11 | | medication orders. | 12 | | (bb) "Pharmacist care" means the provision by a pharmacist | 13 | | of medication therapy management services, with or without the | 14 | | dispensing of drugs or devices, intended to achieve outcomes | 15 | | that improve patient health, quality of life, and comfort and | 16 | | enhance patient safety. | 17 | | (cc) "Protected health information" means individually | 18 | | identifiable health information that, except as otherwise | 19 | | provided, is: | 20 | | (1) transmitted by electronic media; | 21 | | (2) maintained in any medium set forth in the | 22 | | definition of "electronic media" in the federal Health | 23 | | Insurance Portability and Accountability Act; or | 24 | | (3) transmitted or maintained in any other form or | 25 | | medium. | 26 | | "Protected health information" does not include |
| | | HB5530 Enrolled | - 18 - | LRB103 37122 RTM 67241 b |
|
| 1 | | individually identifiable health information found in: | 2 | | (1) education records covered by the federal Family | 3 | | Educational Right and Privacy Act; or | 4 | | (2) employment records held by a licensee in its role | 5 | | as an employer. | 6 | | (dd) "Standing order" means a specific order for a patient | 7 | | or group of patients issued by a physician licensed to | 8 | | practice medicine in all its branches in Illinois. | 9 | | (ee) "Address of record" means the designated address | 10 | | recorded by the Department in the applicant's application file | 11 | | or licensee's license file maintained by the Department's | 12 | | licensure maintenance unit. | 13 | | (ff) "Home pharmacy" means the location of a pharmacy's | 14 | | primary operations. | 15 | | (gg) "Email address of record" means the designated email | 16 | | address recorded by the Department in the applicant's | 17 | | application file or the licensee's license file, as maintained | 18 | | by the Department's licensure maintenance unit. | 19 | | (Source: P.A. 102-16, eff. 6-17-21; 102-103, eff. 1-1-22; | 20 | | 102-558, eff. 8-20-21; 102-813, eff. 5-13-22; 102-1051, eff. | 21 | | 1-1-23; 103-1, eff. 4-27-23.) |
|